ProCE Banner Activity

SPOTLIGHT: Phase III Study of First-line Zolbetuximab + mFOLFOX6 for Advanced CLDN18.2+/HER2- Gastric/Gastroesophageal Junction Adenocarcinoma

Conference Coverage
Slideset

Addition of zolbetuximab to mFOLFOX6 improved PFS and OS compared with mFOLFOX alone for previously untreated patients with advanced CLDN18.2+/HER2- gastric/gastroesophageal junction adenocarcinoma.

Released: January 25, 2023

Expiration: January 24, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Bristol Myers Squibb

Incyte Corporation

Merck Sharp & Dohme Corp

Seagen Inc.